This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NovaBay Pharmaceuticals Provides Second Quarter 2012 Financial Results

Aganocide ® Compounds

NovaBay's first-in-class Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides possess a very low likelihood that bacteria or viruses will be able to develop resistance, which is critical for advanced anti-infectives. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay's clinical development activities are focused on three disease areas:
  • Dermatology - Partnered with Galderma, a leading dermatology company, to develop a formulation of NVC-422 for treatment of highly contagious skin infection, impetigo, caused primarily by S. aureus and Group A Beta-hemolytic streptococci. A major global Phase 2b clinical study is planned for 2012.  
  • Ophthalmology - NovaBay is developing an eye drop formulation of NVC-422 for treating adenoviral conjunctivitis. Enrollment into a global Phase 2b clinical study has begun with top-line data expected in the first half of 2013.  
  • Urology NovaBay's urinary catheter irrigation solution containing NVC-422 is currently enrolling patients in its Phase 2 proof-of-concept clinical studies, with the goal of reducing the incidence of urinary catheter blockage and encrustation (UCBE) and associated urinary tract infections. The Company reported positive data from Part A of this study and expects to announce top-line results from Part B later in 2012.

NeutroPhase ®

NovaBay is also developing NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. We believe that NeutroPhase is the only patented pure hypochlorous acid solution available and has the potential to be best suited to treat the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers. For additional information, visit: .

Forward-Looking Statements

This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the expected timing of enrollment and commencement of clinical trials, expected timing of receipt and announcement of results of clinical studies, and expected future financial results . Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to NovaBay and Aganocide compounds, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Stay informed on NovaBay's progress:
(a development stage company)
  June 30, December 31,
  2012 2011
(in thousands, except per share data) (unaudited)  
Current assets:    
Cash and cash equivalents  $ 4,653  $ 8,428
Short-term investments   5,720  5,710
Accounts receivable  9  3
Prepaid expenses and other current assets  506  417
Total current assets  10,888  14,558
Property and equipment, net   1,069  1,270
Other assets  117  135
TOTAL ASSETS  $ 12,074  $ 15,963
Current liabilities:    
Accounts payable  $ 901  $ 472
Accrued liabilities   1,306  1,061
Deferred revenue  1,537  1,305
Total current liabilities  3,744  2,838
Deferred revenues -- non-current  539  945
Deferred rent  50  115
Warrant liability  2,128  2,721
Total liabilities  6,461  6,619
Stockholders' Equity:    
Preferred stock, $0.01 par value; 5,000 shares authorized; none outstanding at June 30, 2012 and December 31, 2011  —   — 
Common stock, $0.01 par value; 65,000 shares authorized at June 30, 2012 and December 31, 2011; 28,868 and 28,587 issued and outstanding at June 30, 2012 and December 31, 2011, respectively  289  286
Additional paid-in capital  43,427  42,386
Accumulated other comprehensive loss  (62)  (44)
Accumulated deficit during development stage  (38,041)  (33,284)
Total stockholders' equity  5,613  9,344
(a development stage company)
  Three Months Ended June 30, Six Months Ended June 30, Cumulative Period from July 1, 2002 (inception) to
(in thousands, except per share data) 2012 2011 2012 2011 June 30, 2012
License and collaboration revenue  $ 856  $ 4,527  $ 2,172  $ 7,006  $ 52,771
Other revenues  15  —   19  11  45
Total revenue  871  4,527  2,191  7,017  52,816
Operating expenses:          
Research and development  2,378  2,769  4,642  5,689  55,513
General and administrative  1,368  1,318  2,909  2,833  36,563
Total operating expenses  3,746  4,087  7,551  8,522  92,076
Operating income (loss)  (2,875)  440  (5,360)  (1,505)  (39,260)
Non-cash loss (gain) on change in fair value of warrants  628  —   593  —   (139)
Other income (expense), net  27  (11)  22  (42)  1,443
Income (loss) before income taxes  (2,220)  429  (4,745)  (1,547)  (37,956)
Provision for income taxes  (6)  (4)  (12)  (16)  (85)
Net income (loss)  (2,226)  425  (4,757)  (1,563)  (38,041)
Other comprehensive gain (loss):          
Change in unrealized gains (losses) on available-for-sale securities  (20)  4  (18)  (9)  (62)
Total comprehensive income (loss)  $ (2,246)  $ 429  $ (4,775)  $ (1,572)  $ (38,103)
Net loss per share:          
Basic and diluted  $ (0.08)  $ 0.02  $ (0.17)  $ (0.07)  
Shares used in per share calculations:          
Basic and diluted  28,671  23,480  28,621  23,454  
CONTACT: Investors:
         NovaBay Pharmaceuticals, Inc.
         Thomas J. Paulson
         Chief Financial Officer
         Investors and Media:
         The Ruth Group
         Stephanie Carrington / Nicole Greenbaum (Investors)
         (646) 536-7017/7009 /
         Victoria Aguiar (Media)
         (646) 536-7013

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs